Researchers at University Hospital Cologne have developed a serum proteomics model that predicts kidney function decline in patients with autosomal dominant polycystic kidney disease (ADPKD) by identifying six key proteins. This new model outperforms traditional clinical and imaging tools, providing essential insights for early intervention, such as prescribing tolvaptan. The model explained 31.4% of variance in annual estimated glomerular filtration rate (eGFR) decline, and its predictive accuracy was validated on independent cohorts, indicating its potential for clinical application.

Source: nature communications